A Phase 1, Open-Label, Dose-Ranging Study of the PD-1 Probody Therapeutic CX-188 in Adults With Recurrent or Metastatic Solid Tumors
Status: Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2019
Price : $35 *
At a glance
- Drugs CX-188 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Acronyms PROCLAIM-CX-188
- Sponsors CytomX Therapeutics
- 26 Jul 2019 Planned initiation date changed from 1 Jun 2019 to 1 Jan 2020.
- 15 Mar 2019 Planned initiation date changed from 1 Nov 2018 to 1 Jun 2019.
- 16 Oct 2018 New trial record